key: cord-0694630-szn3uc3i
authors: Hunjan, M.K.; Roberts, C.; Karim, S.; Hague, J.
title: Pityriasis Rubra Pilaris like eruption following administration of the BNT163b2 (Pfizer BioNTech) mRNA COVID‐19 vaccine
date: 2021-08-11
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14878
sha: 2635c6d2022fa508991431a552bbf95edc90d026
doc_id: 694630
cord_uid: szn3uc3i

Since the approval of the novel mRNA vaccines for Sars COV‐2 the dermatology community has sought to characterise the adverse cutaneous effects associated with administration of the vaccine. In the BNT162b2 (Pfizer/ BionTech) mRNA vaccine Phase III study, no participants reported cutaneous adverse events aside from injection site reactions (1). We report a case of pityriasis rubra pilaris (PRP) like eruption following administration of the Pfizer‐BioNTech COVID‐19 vaccine.

Since the approval of the novel mRNA vaccines for Sars COV-2 the dermatology community has sought to characterise the adverse cutaneous effects associated with administration of the vaccine.

In the BNT162b2 (Pfizer/ BionTech) mRNA vaccine Phase III study, no participants reported cutaneous adverse events aside from injection site reactions (1) . We report a case of pityriasis rubra pilaris (PRP) like eruption following administration of the Pfizer-BioNTech COVID-19

vaccine.

An otherwise fit and well 51-year-old gentleman presented with a widespread scaly erythematous rash following administration of the Pfizer-BioNTech COVID-19 vaccine. 3 days following the first dose of the vaccine he developed an erythematous scaly rash in his groin and over his knees and treated in the community as psoriasis with Enstilar TM foam and emollients with partial success. A few days following the second vaccine dose at 12 weeks, he noticed the rash worsening with the plaques becoming more confluent affecting 60% of his body surface area. Despite continued treatment with topical therapies his skin continued to worsen and subsequently presented to the acute medical unit where he was found to be mildly hypotensive and tachycardic.

He denied taking any medication preceding the skin eruption.

On examination he had a confluent erythematous mildly scaly skin eruption extending from his scalp to his proximal thighs and both arms with sparing of the periumbilical area. There were scattered erythematous plaques over this lower legs. His nails were normal and clinically there was no evidence of palmoplantar hyperkeratosis. The differential diagnosis included a druginduced psorasisform rash and pityriasis rubra pilaris (PRP).

Histological examination of a skin biopsy showed prominent alternating orthokeratosis and parakeratosis in horizontal and vertical directions. The epidermis showed mild irregular acanthosis with broader rete ridges than expected in a psoriasiform reaction. There was mild and focal spongiosis with slight lymphocytic exocytosis. There was mild perivascular and perifollicular lymphocytic inflammation within the papillary dermis with neutrophils and the very occasional eosinophil seen focally (figure 2). Overall, the histological features were consistent with a diagnosis of PRP.

Blood tests showed revealed a raised C-reactive-protein level, but white cell and eosinophil counts were normal. Serological testing for blood borne viruses and SARs-COV2 PCR was negative. A

This article is protected by copyright. All rights reserved chest x-ray was normal and there was no suggestion of occult malignancy from the history or physical examination. A diagnosis of PRP like eruption was made and the probable trigger thought to be the Pfizer-BionTech COVID-19 vaccine. The patient's condition improved and continues to do so on 20mg of acitretin once daily and topical mometasone 0.1% ointment.

A recent registry of 414 patients who received either of the mRNA COVID-19 vaccines described cutaneous reactions including local injection site reactions, urticarial and morbilliform eruptions but PRP-like eruptions have yet to be described (2) . As described in our case worsening or recurrence was seen in up to 43 % of patients on administration of the 2 nd dose. (2) The aetiology of PRP is not known, but there has been suggestion that CARD-14 mutations could 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris

Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data